Clinical Trial

Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

Enrolling by Invitation

Summary

This is an observational, follow up study of subjects previously enrolled in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL in subjects previously implanted in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study".

Protocol Amendment History 5 changes

critical Primary endpoint(s) modified 2026-08-13

notable Enrollment reduced: 500 -> 108 participants 2026-08-13

minor Trial arms changed: 2 -> 1 2026-08-13

notable Primary completion pushed: 2026-06 -> 2026-09 2026-08-13

minor Completion pushed: 2026-09 -> 2026-12 2026-08-13

Trial Details

NCT Number	NCT07347379
Lead Sponsor	RxSight, Inc.
Conditions	Aphakia Cataract
Enrollment	108 participants
Start Date	2025-11-13
Primary Completion	2026-09 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-12